NCT01567683View on ClinicalTrials.gov

A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

Healthy

Interventions

DRUG

Imiquimod (topical use)

Trial Locations (1)

Unknown

Proinnovera GmbH Phase I Unit, Münster

Sponsors

Lead Sponsor

Moberg Pharma AB

All Listed Sponsors

lead

Moberg Pharma AB

INDUSTRY